BlueAllele, a Minnesota-based developer of gene editing technology, has filed a lawsuit against Intellia Therapeutics (NASDAQ:NTLA) in a federal court in Delaware alleging that Intellia has infringed upon three of its patents for its bio-directional insertion template technology.

BlueAllele said in a statement that Intellia has used its patented platform technology to advance both internal and collaboration programs.

According to Bloomberg, the suit encompasses being done through Intellia’s $100M collaboration with Regeneron (REGN). Bloomberg said Intellia did not immediately respond to a request for comment.

Intellia and Regeneron expanded their collaboration in October to include CRISPR-based gene edited therapies for neurological and muscular diseases. The companies have also been working on therapies to treat ATTR and hemophilia, according to Intellia’s website.